← Back to Clinical Trials
Recruiting NCT03193892

NCT03193892 A National Registry on Chinese Patients With Lymphangioleiomyomatosis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03193892
Status Recruiting
Phase
Sponsor Peking Union Medical College Hospital
Condition Pulmonary Function
Study Type OBSERVATIONAL
Enrollment 1,500 participants
Start Date 2017-01-01
Primary Completion 2026-10-01

Eligibility & Interventions

Sex Female only
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,500 participants in total. It began in 2017-01-01 with a primary completion date of 2026-10-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Pulmonary lymphangioleiomyomatosis (LAM), a disease characterized by diffuse cystic changes in the lung, is a rare disorder that affects almost exclusively women. The main objectives of this study are to accurately evaluate the prevalence of LAM, the status of disease, the diagnosis and treatment, the quality of care, and the health related outcomes in China.

Eligibility Criteria

Inclusion Criteria: 1. Gender: female. 2. Age: no limitation. 3. Diagnosis meets one of the following criteria, (1) definite or probable diagnosis of LAM based on ATS/JRS and ERS criteria. (2) Investigators recommend including of the patient. Exclusion Criteria: 1. Suspected LAM patients without other supporting evidence for LAM diagnosis. 2. No diffuse cystic lesions in the lung. 3. Patients with bilateral cystic lung lesions but the LAM diagnosis cannot be established. 4. Without signed informed consent. 5. Difficult to follow up.

Contact & Investigator

Central Contact

Kai-Feng Xu, M.D.

✉ xukf@pumch.cn

📞 86-10-69155039

Frequently Asked Questions

Who can join the NCT03193892 clinical trial?

This trial is open to female participants only, studying Pulmonary Function. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03193892 currently recruiting?

Yes, NCT03193892 is actively recruiting participants. Contact the research team at xukf@pumch.cn for enrollment information.

Where is the NCT03193892 trial being conducted?

This trial is being conducted at Beijing, China.

Who is sponsoring the NCT03193892 clinical trial?

NCT03193892 is sponsored by Peking Union Medical College Hospital. The trial plans to enroll 1,500 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology